Showing results (51-60 of 65) with videos related to
Sort By:
Pageof 7
Cancer Research|July 26, 2000
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceR T Reilly, M B Gottlieb, A M Ercolini, et al.Zeitschrift Fur Gastroenterologie|February 4, 2010
Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximabM A Stange, O Tutarel, S Pischke, et al.The Journal of Urology|March 1, 1994
Demonstration of a rational strategy for human prostate cancer gene therapyM G Sanda, S R Ayyagari, E M Jaffee, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathyK Bieganowska, P Höllsberg, G J Buckle, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 5, 2000
Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous systemM G Ewend, R C Thompson, R Anderson, et al.Proceedings of the National Academy of Sciences of the United States of America|September 3, 1996
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene productA Y Huang, P H Gulden, A S Woods, et al.Gene Therapy|July 5, 2001
Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectorsJ G Wesseling, P J Bosma, V Krasnykh, et al.International Journal of Radiation Oncology, Biology, Physics|November 10, 2000
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survivalA Chakravarthy, R A Abrams, C J Yeo, et al.Cancer Research|June 5, 2001
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinomaP Argani, C Rosty, R E Reiter, et al.United European Gastroenterology Journal|November 5, 2015
A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenibA G Duffy, S V Ulahannan, L Cao, et al.Pageof 7